Recent studies have revealed differential control of amino acids in epithelial cancer cells, mesenchymal cells, and immunocytes, suggesting the potential for amino acids and their transporters, i.e., solute carriers (SLC), in T-cell immunotherapy for cancer [26]. This evidence concerns the gene CCL21 and cancer.